Visual function improvement in patients with macroprolactinomas treated with bromocriptine.
We studied eight patients who had visual field defects secondary to prolactin-secreting macroadenomas and who had improved visual function with bromocriptine treatment without surgery or radiation. We recommend bromocriptine as a primary treatment for prolactin-secreting macroadenomas. If therapy is effective, continued regular neuro-ophthalmologic, endocrine, and imaging studies are necessary, because treatment with bromocriptine must be continued indefinitely.
Lesser
R L
RL
Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, Connecticut 06510.
Zheutlin
J D
JD
Boghen
D
D
Odel
J G
JG
Robbins
R J
RJ
D000328:Adult; D000368:Aged; D001971:Bromocriptine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000188:drug therapy*; D011388:Prolactin / Q000097:blood; D015175:Prolactinoma / Q000188:drug therapy*; D014057:Tomography, X-Ray Computed; D014785:Vision, Ocular / Q000187:drug effects*; D014792:Visual Acuity / Q000187:drug effects; D014794:Visual Fields / Q000187:drug effects
D001971:Bromocriptine; D011388:Prolactin